299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

4 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03312140 (ClinicalTrials.gov)	November 6, 2014	4/10/2017	Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis	Examination of the Lipid Metabolism of the Liver After Choline Substitution in Cystic Fibrosis	Cystic Fibrosis Liver Disease	Drug: Choline Chloride	University Hospital Tuebingen	NULL	Completed	18 Years	N/A	Male	10	N/A	NULL
2	NCT01070446 (ClinicalTrials.gov)	October 2007	10/2/2010	Choline Nutrition in Children With Cystic Fibrosis	Choline Nutrition in Children With Cystic Fibrosis	Cystic Fibrosis	Dietary Supplement: Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1	University of British Columbia	Cystic Fibrosis Foundation (US)	Completed	5 Years	17 Years	Both	34	N/A	Canada
3	NCT00686361 (ClinicalTrials.gov)	October 2007	26/5/2008	Choline Nutrition in Children With Cystic Fibrosis (CF)	To Investigate Whether Choline Supplementation in Children With CF Will Correct Biochemical Markers of Choline Deficiency and Improve Plasma Indices of Methylation Capacity and Redox Status and Result in Decreased Pro-inflammatory Cytokines	Cystic Fibrosis	Drug: Choline supplementation	University of British Columbia	Cystic Fibrosis Foundation Therapeutics	Completed	5 Years	17 Years	Both	34	N/A	Canada
4	NCT00406536 (ClinicalTrials.gov)	January 2007	29/11/2006	Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI	Phase II Study: LYM-X-SORB™, an Organized Lipid Matrix: Fatty Acids and Choline in CF	Cystic Fibrosis;Pancreatic Insufficiency	Dietary Supplement: Lym-X-Sorb powder;Dietary Supplement: Placebo powder	Avanti Polar Lipids, Inc.	National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	6 Years	17 Years	Both	110	Phase 2	United States